한빛사
>
한빛사논문
한빛사논문
- 조회52
Biosens. Bioelectron., Jan 17 2025, 273 S0956-5663(25)00055-7 | https://doi.org/10.1016/j.bios.2025.117181
Reactive EEG Biomarkers for Diagnosis and Prognosis of Alzheimer's Disease and Mild Cognitive Impairment
Soonhyouk Lee a,b, Changtae Hahn c, Eunyoung Seong b, Hak Soo Choi d
aCenter for Integrated Smart Sensors, N1, 291 Daehak-ro, Yuseong-gu, Daejeon, South Korea
bMegnosis Co., Ltd., 11-3, Techno 1-ro, Yuseong-gu, Daejeon, South Korea
cDepartment of Psychology, The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, South Korea
dGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA
Corresponding authors: Soonhyouk Lee, Changtae Hahn
aCenter for Integrated Smart Sensors, N1, 291 Daehak-ro, Yuseong-gu, Daejeon, South Korea
bMegnosis Co., Ltd., 11-3, Techno 1-ro, Yuseong-gu, Daejeon, South Korea
cDepartment of Psychology, The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, South Korea
dGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02129, USA
Corresponding authors: Soonhyouk Lee, Changtae Hahn
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative condition characterized by progressive cognitive decline with currently no effective treatment available. One of the most critical areas in AD research is the identification of reliable biomarkers, which are essential for accurate diagnosis, prognostic assessment, and the development of targeted therapies. In this study, we introduce two novel reactive EEG (rEEG) biomarkers aimed at enhancing the diagnosis of AD and mild cognitive impairment (MCI). These biomarkers, previously unexplored in the literature, offer new insights into differentiating between various cognitive states. The first biomarker demonstrates a significant ability to distinguish between AD patients and normal controls (NC), while also effectively distinguishing MCI patients from NC. The second biomarker is designed to identify a subset of AD patients exhibiting hyperconductivity or hyperactivity, characterized by distinctive neural electrical patterns. A cohort of 90 elderly participants (mean age 76.63 ± 6.08 years) was recruited, including 30 AD patients, 30 individuals with MCI, and 30 NC subjects. Psychiatric diagnoses of participants were made by qualified professionals at Daejeon St. Mary's Hospital, The Catholic University of Korea, utilizing comprehensive neuropsychological assessments. Notably, the rEEG biomarkers achieved accuracies of 95%, 95%, and 98% in distinguishing between AD and NC, AD and MCI, and MCI and NC groups, respectively. These results underscore the potential of rEEG as a highly accurate and reliable diagnostic tool for cognitive impairments, including AD and MCI.
논문정보
- Research article
- 2025년 01월 (BRIC 등록일 2025-01-22)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 뇌인지과학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 ID
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
